CCM2 Mediates Death Signaling by the TrkA Receptor Tyrosine Kinase  by Harel, Liraz et al.
Neuron
Report
CCM2 Mediates Death Signaling by the
TrkA Receptor Tyrosine Kinase
Liraz Harel,1 Barbara Costa,1,10 Marianna Tcherpakov,1,10 Marc Zapatka,2 Andre Oberthuer,3 Loen M. Hansford,4
Milijana Vojvodic,4 Zehava Levy,1 Zhe-Yu Chen,5 Francis S. Lee,6 Smadar Avigad,7 Isaac Yaniv,7 Leming Shi,8
Roland Eils,2,9 Matthias Fischer,3 Benedikt Brors,2 David R. Kaplan,4 and Mike Fainzilber1,*
1Department of Biological Chemistry, Weizmann Institute of Science, 76100 Rehovot, Israel
2German Cancer Research Center, Department Theoretical Bioinformatics B080, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
3Department of Pediatric Oncology and Hematology and Center for Molecular Medicine Cologne (CMMC), University of Cologne,
Children’s Hospital, Kerpener Strasse 62, 50924 Cologne, Germany
4Cell Biology Program, Hospital for Sick Children, 101 College Street, Toronto, Ontario M5G 1L7, Canada
5Department of Neurobiology, School of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China
6Departments of Psychiatry and Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA
7Pediatric Oncology, Felsenstein Medical Research Center, Schneider Children’s Medical Center of Israel, Petah-Tikva 49202, Israel
8National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079, USA
9Theoretical Bioinformatics, Department Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology
(IPMB), University of Heidelberg, 69120 Heidelberg, Germany
10These authors contributed equally to this work
*Correspondence: mike.fainzilber@weizmann.ac.il
DOI 10.1016/j.neuron.2009.08.020SUMMARY
The TrkA receptor tyrosine kinase is crucial for differ-
entiation and survival of nerve-growth-factor-depen-
dent neurons. Paradoxically, TrkA also induces cell
death in pediatric tumor cells of neural origin, via an
unknown mechanism. Here, we show that CCM2,
a gene product associated with cerebral cavernous
malformations, interacts with the juxtamembrane
region of TrkA via its phosphotyrosine binding (PTB)
domain and mediates TrkA-induced death in diverse
cell types. Both the PTB and Karet domains of CCM2
are required for TrkA-dependent cell death, such that
the PTB domain determines the specificity of the
interaction, and the Karet domain links to death path-
ways. Downregulation of CCM2 in medulloblastoma
or neuroblastoma cells attenuates TrkA-dependent
death. Combined high expression levels of CCM2
and TrkA are correlated with long-term survival in
a large cohort of human neuroblastoma patients.
Thus, CCM2 is a key mediator of TrkA-dependent
cell death in pediatric neuroblastic tumors.
INTRODUCTION
The trk family of receptor tyrosine kinases (RTK) mediates neuro-
trophin prosurvival signaling in the nervous system (Huang and
Reichardt, 2003). Paradoxically, TrkA has also been reported
to induce cell death in tumor cells of neural origin (Hansen
et al., 2007; Jung and Kim, 2008; Lavoie et al., 2005; Muragaki
et al., 1997). Such death signaling is highly atypical for RTKs,
and although similar observations have been published for
a few other receptors (Chao, 2003), these reports comprisea negligible fraction of the extensive literature in the field. The
molecular mechanisms whereby TrkA or any other RTK induce
death rather than its normal prosurvival signaling are not known.
Trk-induced death may be an important determinant of
disease progression in pediatric tumors of neural origin, specifi-
cally neuroblastoma and medulloblastoma. Medulloblastomas
are the most common malignant tumors of the central nervous
system in children (Ullrich and Pomeroy, 2003). Localized
expression of TrkA or TrkC has been detected in concentrations
of apoptotic or differentiating medulloblastoma cells (Eberhart
et al., 2001; Ohta et al., 2006). Moreover, TrkC is a positive prog-
nostic indicator in medulloblastoma (Gulino et al., 2008) and has
been reported to induce apoptosis in medulloblastoma cells
(Kim et al., 1999). A similar situation occurs in neuroblastomas,
which are derived from primitive cells of the sympathetic nervous
system. Most infants diagnosed with neuroblastoma before
1 year of age undergo complete regression of the disease,
whereas older children frequently have metastatic disease that
is extremely difficult to treat (Brodeur, 2003). Tumors with posi-
tive prognosis usually express TrkA and are more likely to be
found in younger patients (Brodeur, 2003). Engineering of medul-
loblastoma cell lines to express TrkA caused NGF-dependent
death of the TrkA-expressing cells (Chou et al., 2000; Muragaki
et al., 1997), and similar data were recently reported in neuro-
blastoma and glioblastoma (Hansen et al., 2007; Lavoie et al.,
2005). Thus, trk activation of cell-death pathways can have
profound effects in pediatric tumors of neural origin.
During the course of a screen for downstream effectors of neu-
rotrophin signaling, we identified CCM2, the protein product of
the cerebral cavernous malformation 2 gene (Figure S1), as an
interactor of TrkA. Here, we show that, when coexpressed with
TrkA, CCM2 mediates TrkA-induced cell death in a diversity of
cell types and that CCM2 knockdown attenuates TrkA-depen-
dent death in both medulloblastoma and neuroblastoma cells.
Furthermore, increased TrkA and CCM2 transcript expressionNeuron 63, 585–591, September 10, 2009 ª2009 Elsevier Inc. 585
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CCM2 Mediates TrkA Death SignalingFigure 1. CCM2 Mediates TrkA-Dependent
Cell Death
(A) Endogenous levels of CCM2. Immunostaining
for CCM2 using an anti-PTB domain antibody in
PC12 cells transfected with CCM2 versus non-
transfected nnr5 and HEK293 cells. Arrows indi-
cate a PC12 cell transfected with CCM2 versus
an untransfected cell with endogenous back-
ground levels. Scale bars, 10 mm (PC12) or 20
mm (nnr5, HEK293). (B) Transfection of CCM2 to
PC12 results in cell death. PC12 viability 15 hr after
transfection with CCM2 or control vector,
analyzed by FACS. Inset images are cells visual-
ized by live/dead stain, n = 3, **p < 0.01 (viable
cells are green; dead cells are red). (C) PC12 tet-
on cells were transfected with HA-CCM2 cloned
under an inducible promoter and incubated for
24 hr with doxycycline (0.3–1 mg/ml). Cells trans-
fected with CCM2 but not treated with doxycycline
served as control. Expression levels of CCM2 after
treatment were determined by western blot (lower
panel), with b-tubulin as a loading control. Viability
is presented as percent of control, n = 3, *p < 0.05.
(D) Viability of HEK293 cells measured by XTT 24
hr after cotransfection with CCM2 or control
pcDNA3 vector and TrkA, n = 3, *p < 0.05.in a large cohort of neuroblastoma patients correlates strikingly
with positive clinical outcome. We propose that CCM2 is a critical
mediator of TrkA-induced cell death and that this mechanism
may be a key determinant of regression in neuroblastoma.
RESULTS
CCM2 Induces TrkA-Dependent Cell Death
PC12 cells express undetectable to very low levels of CCM2
(Figure 1A) and are an established model for study of TrkA
effects. Surprisingly, CCM2 transfection to PC12 cells caused
extensive cell death (Figure 1B). Doxycycline induction of
CCM2 expression in transfected Tet-on PC12 revealed a correla-
tion between the degree of expression of CCM2 and cell-death
levels (Figure 1C). In contrast, there was no significant reduction
in cell viability upon CCM2 transfection to nnr5, a TrkA-deficient
derivative of PC12, or to HeLa or HEK293 cells that do not express
any neurotrophin receptors (Figure 1D and data not shown).
Strikingly, cotransfection of CCM2 with TrkA to these different
cell types caused robust induction of cell death (Figure 1D and
data not shown), indicating that CCM2 requires coexpression of
TrkA for death signaling. Although the p75 receptor is more often
implicated in cell-death pathways than TrkA (Bronfman and Fain-
zilber, 2004), cotransfection of p75 with CCM2 had no effect on
HEK cell viability (data not shown), and the fact that death is
observed in HEK cells transfected only with TrkA and CCM2
(Figure 1D) suggests that p75 is not required.
CCM2 Interacts with the TrkA Juxtamembrane Region
and Requires Active Receptor to Signal Cell Death
The presence of a PTB domain in CCM2 and its homology to the
Dab/Shc family suggested the possibility of a direct interaction586 Neuron 63, 585–591, September 10, 2009 ª2009 Elsevier Inc.with TrkA. Coimmunoprecipitation (co-i.p.) experiments in trans-
fected HEK293 cells indeed revealed an interaction between
CCM2 and all three trk family members, TrkA, TrkB and TrkC,
but no interaction with p75 (Figure 2A). The CCM2-TrkA interac-
tion was not dependent on addition of NGF. Phosphorylation
status of the trks was not markedly changed by CCM2 cotrans-
fection in HEK cells (Figure 2B), and although CCM2 interacts
with all three trks, death induction in cotransfection experiments
was observed only with TrkA (Figure 2C). Application of BDNF or
NT-3 to HEK cells coexpressing CCM2 with TrkB or TrkC did not
affect cell viability (data not shown). Co-i.p.s with TrkA deletion
mutants localized the CCM2 interaction site to residues
464–484 in the juxtamembrane (Figure 2D), a region of the
receptor previously reported to be required for dynein interac-
tion (Yano et al., 2001), neuritogenesis (Peng et al., 1995), and
recycling (Chen et al., 2005). This interaction site was verified
by in vitro pulldown of CCM2 with a biotinylated synthetic
TrkA458-484 peptide (Figure 2E). A TrkA mutant lacking this
epitope (TrkAD2, Chen et al., 2005) lost the capacity to induce
death with CCM2, while a TrkB chimera containing the TrkA
juxtamembrane region [TrkB(AJM); Chen et al., 2005] gained
the capacity to induce death with CCM2 (Figure 2C). Notably,
there is no tyrosine in this CCM2-binding TrkA sequence,
although it is adjacent to the Shc site (490Y). This was further
verified by co-i.p. of CCM2 with TrkA Y490A, Y490F, and
Y785F mutants, corresponding to the Shc and PLCg binding
sites, respectively (Figure S2A). These co-i.p.s indicate that
CCM2 does not require complete phosphorylation of TrkA for
the interaction. Nonetheless, the kinase activity of TrkA is
required for death induction by CCM2, as shown in experiments
with the TrkA inhibitor K252A (Figure S2B). Furthermore, co-
transfection with the kinase-dead TrkA mutant K538A revealed
Neuron
CCM2 Mediates TrkA Death SignalingFigure 2. CCM2 Interacts with the TrkA Jux-
tamembrane Region and Requires Active
Receptor to Signal Cell Death
(A) Coimmunoprecipitation (co-i.p.) of HA-CCM2
with TrkA, TrkB, TrkC, and p75 from HEK293 co-
transfected cells. The blot was probed with anti-
pan trk and p75 antibody. L, lysate. (B) Activation
status of trk receptors monitored by i.p. with
a pan-trk antibody from HEK293 cells cotrans-
fected with FLAG-CCM2 or with a control vector.
The i.p. blot was probed with pan-trk and phos-
pho-tyrosine (pY) antibodies, while CCM2 expres-
sion was verified in lysates with anti FLAG. (C)
Viability of HEK293 cells cotransfected with
CCM2 or control vector and receptor constructs
as indicated, measured by XTT 24 hr following
transfection, n = 3, *p < 0.05, ***p < 0.001. TrkAD2-
TrkA with juxtamembrane deletion of residues
473–493, TrkB(AJM)- TrkB chimera containing
TrkA juxtamembrane, TrkA KD- TrkA kinase dead
mutant K538A. (D) Co-i.p. of FLAG-CCM2 with
deletion mutants of TrkA from transfected
HEK293 cells. Arrows indicate TrkA-specific
bands. (E) In vitro pull down of biotinylated
synthetic peptide corresponding to the indicated
TrkA sequence and control peptide with recombi-
nant His-CCM2 protein.interaction with CCM2 (Figure S2C), but no death induction
(Figure 2C).
Both Domains of CCM2 Are Required for Induction of
Cell Death
We generated deletion constructs of mouse CCM2 restricted to
either the N-terminal 227 amino acids containing the PTB or the
C-terminal region comprising residues 228–453 (designated
Karet; Figures 3A and S1A) and tested these by cotransfection
with TrkA in HEK293 cells. The PTB domain pulled down TrkA
in these experiments, while in contrast no direct interaction
was observed with the Karet construct (Figure 3B). Confirmation
that the PTB region is sufficient to interact with the TrkA458-484
sequence was obtained by in vitro pull-down with the biotiny-
lated peptide (Figure 3C). A F217V mutation in full-length
CCM2 and in the PTB construct, previously shown to impair
binding to CCM1 (Zawistowski et al., 2005), also attenuated
binding to TrkA (Figure 3D). Neither of the deletion constructs
nor the F217V mutation caused significant reduction in the
viability of transfected PC12 cells (Figure 3E). Similar results
were obtained by cotransfection of the constructs together
with TrkA to HEK293 cells (data not shown). We then tested
the effects of substituting the PTB domain of CCM2 with that
of Shc. The resulting CSK construct (CCM2-Shc PTB-Karet;
Figure 3A) effectively induced death with all three trk family
members upon cotransfection in HEK cells (Figure 3F). Taken
together, these data indicate that both regions of CCM2 arerequired for death signaling, with the PTB domain determining
receptor specificity and efficacy of outcome by virtue of interac-
tion with a juxtamembrane epitope in the receptor, and the Karet
domain linking to death pathways (Figure 3G). The requirement
for the C-terminal region in death induction suggested its
name, from the Hebrew Karet meaning to sever, describing an
unusual form of biblical sanction (Genesis, Chapter 17, Verses
10–14).
Downregulation of Endogenous CCM2 in Pediatric
Tumor Cells Rescues from NGF-Induced TrkA-
Dependent Cell Death
We next examined whether CCM2 is involved in TrkA-mediated
cell death in Med283-TrkA cells (MB-TrkA). CCM2 is endoge-
nously expressed in these cells, in partial colocalization with
TrkA (Figure 4A). Lentiviral shRNA transduction with anti-CCM2
caused 50% reduction in the expression of CCM2 transcripts,
while levels were not affected in cells transduced with control
shRNA (Figure S3A). The cell lines were then treated with NGF
(100 ng/ml) for 48 hr, and cell viability was analyzed. As shown
in Figure 4B, downregulation of CCM2 in MB-TrkA rescued
the cells from NGF-induced TrkA-dependent cell death. NGF
caused death of 50% of the cells from the control shRNA
population over the time course of the experiment, similar to
the magnitude of effect seen in the parental cell line. Expression
of a chicken CCM2 construct in the human CCM2-downregu-
lated cells caused renewed death, confirming the specificity ofNeuron 63, 585–591, September 10, 2009 ª2009 Elsevier Inc. 587
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CCM2 Mediates TrkA Death SignalingFigure 3. Both Subdomains of CCM2 Are Required for Induction of
Cell Death
(A) Schematic of domain predictions in CCM2 and in CSK (CCM2-Shc
PTB-Karet) constructs, indicating amino acid residue numbers. (B) Co-i.p. of
HA-CCM2, HA-PTB, or HA-Karet with TrkA from cotransfected HEK293 cells.
(C) Precipitation of the PTB domain of CCM2 by biotinylated TrkA synthetic
peptide as described in Figure 2E. (D) Co-i.p. of HA-CCM2 and HA-F217V
with TrkA from cotransfected HEK293 cells. (E) PC12 cells were transfected
with CCM2, PTB, Karet domain or the CCM2 F217V mutant. Cell viability
was analyzed by FACS 18 hr after transfection, n = 5, ***p < 0.001. (F) Viability
of HEK293 cells cotransfected with CSK or control vector and TrkA, TrkB, or
TrkC receptor constructs as indicated, measured by XTT 48 hr following trans-
fection, n = 3, **p < 0.01, ***p < 0.001. (G) A schematic model indicating the
domain interactions of CCM2 and TrkA required for death signaling.588 Neuron 63, 585–591, September 10, 2009 ª2009 Elsevier Inc.the human-targeted shRNA effect (Figure 4B). Previous studies
have suggested that NGF-induced death in medulloblastoma-
TrkA cells is via apoptotic pathways (Chou et al., 2000), hence
we measured caspase activity in both parental and shRNA-
expressing cells. MB-TrkA parental and control shRNA-express-
ing cells exhibited increased caspase 3/7 activity and elevated
levels of cleaved caspase 3 upon NGF treatment, while signifi-
cantly lower elevations were seen in CCM2 shRNA-expressing
cells (Figure S4).
TrkA induces apoptosis in neuroblastoma NGP cells by a cas-
pase-3-dependent mechanism (Lavoie et al., 2005). We found
that NGP cells also express endogenous CCM2 (Figure 4C)
and then tested the effects of lentivirus-mediated delivery of
anti-CCM2 shRNAs on TrkA-induced death. NGP cell lines
stably expressing anti-CCM2 shRNA revealed a reduction of
more than 80% in CCM2 levels compared to parental cells or
cells expressing control shRNA (Figure S3B). Adenovirus-medi-
ated TrkA expression in parental NGP cells caused a reduction of
50% in cell viability, as previously described (Lavoie et al.,
2005). Similar results were obtained in NGP cells expressing
control shRNA, while cells in which CCM2 had been downregu-
lated by specific shRNA showed increased viability and reduced
TrkA-induced death (Figure 4D). These data indicate that endog-
enous CCM2 is a key factor in TrkA-dependent cell death of both
medulloblastoma and neuroblastoma cells.
CCM2 and TrkA Coexpression Correlates with Positive
Clinical Outcome in Neuroblastoma Patients
The data summarized above indicate that CCM2 mediates TrkA-
induced cell death in diverse cell types, most interestingly in cell
lines derived from pediatric neuroblastic tumors. To address
the clinical significance of this finding, we analyzed expres-
sion-level data for CCM2 and TrkA in genome-wide gene
expression profiles from a cohort of 478 pretreatment neuroblas-
toma samples from patients at all stages and clinical courses
of disease (MAQC-II, unpublished). Clinical covariables are
summarized in Table S1. To assess the predictive relationship
between TrkA, CCM2, and survival, patients were assigned to
a training set (n = 244) and an independent test set (n = 234).
In both cohorts, we observed no correlation of CCM2 and TrkB
by Spearman’s rank correlation, while for TrkC we observed
a weak correlation only in the test set (rho = 0.14, p = 0.029)
but not in the training set. In contrast, a strong correlation of
CCM2 and TrkA expression was identified in both sets (training
set: rho = 0.27, p < 1.764e-5, test set: rho = 0.38, p < 1.686e-9).
We then assessed the impact of TrkA and CCM2 expression
levels on event-free survival (EFS) and overall survival (OS) of
the patients. To avoid overfitting (Taylor et al., 2008), we defined
expression-level thresholds for CCM2 and TrkA on the training
set using maximal selected rank statistics (Hothorn and Lausen,
2003) (Figures 5A and 5B) and calculated Kaplan-Meier esti-
mates to compare the outcome for patients with expression
levels below or above threshold. Above-threshold expression
of both TrkA and CCM2 are strongly correlated with overall
and event-free survival of neuroblastoma patients (Figures 5C,
5D, and S5). This correlation has been extensively documented
for TrkA in the literature (Brodeur, 2003) but has not been
shown previously for CCM2. In multivariate Cox hazard models
Neuron
CCM2 Mediates TrkA Death Signalingincluding stage, age at diagnosis, MYCN, and TrkA, the CCM2
effect could not be separated from TrkA due to the high correla-
tion of the expression levels (data not shown). Similar analyses
for other neurotrophin receptor or CCM genes failed to show
any statistically significant correlation between expression levels
and outcome for patients, apart from a weak effect on EFS for
TrkC (see Figure S6 for TrkB and TrkC, Figure S7 for p75, and
Figure S8 for CCM1 and CCM3). In summary, these data strongly
substantiate the importance and specificity of TrkA signaling via
CCM2 for clinical outcome in neuroblastoma patients.
DISCUSSION
Our results establish CCM2 as a molecular link between TrkA
signaling, caspase activation, and cell death. Death signaling
by RTKs has been enigmatic, given the usual propensity of these
receptors to generate survival or proliferation signals. We have
shown that CCM2 links TrkA to cell death pathways via a PTB-
mediated interaction with the juxtamembrane region of TrkA,
connecting to death signaling pathways through the Karet
domain. Downregulation of CCM2 in medulloblastoma or neuro-
blastoma cells attenuates TrkA-dependent death, and combined
high expression levels of CCM2 and TrkA are correlated with
long-term survival in a large cohort of human neuroblastoma
patients. Thus, CCM2 is a key mediator of TrkA-dependent cell
death, and this mechanism may be critical in pediatric neuro-
blastic tumors.
CCM2, like other CCM genes, lacks any obvious enzymatic
domains and is therefore thought to function as a scaffolding
or adaptor molecule. The CCM2 PTB domain interaction with
Figure 4. Downregulation of CCM2 Rescues Medullo-
blastoma and Neuroblastoma Cells from TrkA-Depen-
dent Death
(A) Colocalization of CCM2 (PTB Ab) and TrkA in Med283-TrkA
(MB-TrkA) medulloblastoma cells. Scale bar, 10 mm. (B) Stable
lines of MB-TrkA transduced with control shRNA or CCM2
shRNA were treated with NGF (100 ng/ml) for 48 hr and
analyzed by XTT. Specificity of the shRNA phenotype was
tested by additional transduction with chicken CCM2
(chCCM2) or control (GFP) expression vectors to a CCM2-
downregulated line as indicated. Results are presented as
percent of viability of NGF-treated cells versus untreated cells,
n = 4, **p < 0.01, ***p < 0.001. (C) Endogenous levels of CCM2
(PTB Ab) in NGP neuroblastoma cells. Scale bar, 10 mm. (D)
Stable CCM2 shRNA or control shRNA transduced NGP lines
were infected with TrkA adenovirus or control virus. Viability
was measured by XTT 72 hr postinfection, and results are pre-
sented as percent of viability of TrkA-infected cells versus
control-infected cells, n = 4, ***p < 0.001.
Figure 5. Increased CCM2 and TrkA
Expression in Neuroblastoma Correlate
with Improved Outcome for Patients
(A and B) Selected expression intensity thresholds
in patient training (A) and test (B) sets. The histo-
grams show expression intensity distributions for
CCM2 and TrkA in both sets. The thresholds
selected by applying maxstat on overall survival
in the training set are denoted by the dashed
vertical line. (C and D) Kaplan-Meier curves for
overall survival (OS) in training (C) and test (D)
sets in relation to CCM2 and TrkA expression.
Patients were assigned to groups according to
their gene expression status as shown in the insets
in each panel.Neuron 63, 585–591, September 10, 2009 ª2009 Elsevier Inc. 589
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CCM2 Mediates TrkA Death SignalingTrkA is at a site lacking a tyrosine residue, further arguing that
CCM2 serves an adaptor or linker function rather than directly
impacting on TrkA signaling. Indeed, the functional interaction
site on TrkA is a specific segment of the juxtamembrane
domain implicated in receptor internalization and recycling
(Chen et al., 2005), and transfer of this interaction site to
TrkB conferred a death-induction gain of function with
CCM2. Moreover, targeting of the CSK chimera to the Shc
binding site in the juxtamembrane domain of TrkB and TrkC
also conferred death induction in transfected HEK cells. This
gain of function must be due to linkage of the trks to Karet-
mediated death pathways rather than interference with Shc
signaling, since HEK cells are not dependent on trk signaling
for viability, and the CSK construct had no effects on HEK
cell viability in the absence of cotransfected trks. Pharmaco-
logical manipulation of RTK endocytic trafficking can have
profound effects on signaling outcome, suggesting that the
CCM2-mediated switch of TrkA signaling from life to death
might be via changes in subcellular localization or trafficking
of the receptor. Notably, although p75 is more usually consid-
ered the death-inducing neurotrophin receptor, biochemical
and functional experiments, as well as patient expression
profiles, do not support a role for p75 in the TrkA-CCM2 death
pathway.
Loss-of-function mutations in CCM2 cause endothelial cell
dysfunction and loss of vascular integrity in animal models
(Kleaveland et al., 2009; Whitehead et al., 2009), and in humans
contribute to familial cerebral cavernous malformations, pre-
senting as vascular lesions of the central nervous system (Akers
et al., 2009; Pagenstecher et al., 2009). Although CCM disease-
related phenotypes are most prominent in the vasculature,
CCM2 is ubiquitously expressed in many cell and tissue types,
including within the nervous system (Plummer et al., 2006).
Moreover, CCM2 interacts with CCM3, another CCM gene
widely expressed in the nervous system (Goudreault et al.,
2009). A very recent study demonstrated that CCM3 induces
apoptosis when overexpressed in cell culture (Chen et al.,
2009). Although it is intriguing to speculate that CCM complexes
might influence early development of neural-crest-derived cells
via TrkA death signaling, the neuroblastoma patient expression
analyses do not support a role for CCM1 or CCM3 in deter-
mining outcome of the disease. Neuroblastic tumors may arise
from overgrowth of neural crest cells in early development
(Nakagawara, 2004), and early diagnosed neuroblastoma that
undergo spontaneous regression were shown to express TrkA
(Brodeur, 2003). The strong correlation we find between high
expression levels of CCM2 and TrkA with prolonged survival of
human patients, and the restriction of this correlation to TrkA
and CCM2 alone among the trk and CCM genes, argues for
a specific functional role of TrkA-CCM2 signaling in tumor
regression. Further studies will be required to delineate all the
steps in this pathway and to assess its impact on other recep-
tors and other types of tumors. Given the prominent roles of
many kinases as oncogenes and as drivers of proliferation, the
identification of CCM2 as a molecular entry point to a mecha-
nism for RTK-induced death, and the ability to transfer this
mechanism to other receptors via chimeric mutants, may have
wide implications.590 Neuron 63, 585–591, September 10, 2009 ª2009 Elsevier Inc.EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
PC12, HEK293, and nnr5 cells were cultured in DMEM and 10% FBS as
described (Bronfman et al., 2003; Tcherpakov et al., 2002). Medulloblastoma
D283MED-TrkA (MB-TrkA) and neuroblastoma NGP cells were grown in
RMPI-1640 and 10% FBS as described (Lavoie et al., 2005; Muragaki et al.,
1997). PC12 cells were transfected by electroporation (Tcherpakov et al.,
2002), and stable colonies were selected under 0.5 mg/ml geneticin. shRNA
transduction in MB-TrkA and NGP was with lentivirus (Sigma-Aldrich) at
20-fold multiplicity of infection (MOI) and selection under 0.5–1 mg/ml puro-
mycin. Specificity of the CCM2 shRNA knockdown phenotype was tested in
medulloblastoma cells by a second transduction of 20 MOI lentivirus encoding
chicken CCM2 or GFP as a control, prepared in pLenti6/V5 DEST (Invitrogen).
CCM2 Constructs
CCM2 constructs in pCDNA3 were haemagglutinin (HA) tagged at the
N terminus, including full-length murine CCM2 (HA-CCM2), the N-terminal
1–227 amino acid residues (designated HA-PTB), and residues 228–453
(designated HA-Karet). An F217V mutant clone (HA-F217V) was generated
by site-directed mutagenesis using PFU polymerase (Stratagene). C-terminal
FLAG-tagged CCM2 (FLAG-CCM2) was obtained by cloning murine CCM2
into pIRES-hrGFP-1a (Stratagene). A CCM2-Shc chimera was generated by
replacement of the PTB domain in CCM2 with a Shc PTB domain. The chimera,
designated CCM2-Shc PTB-Karet, was cloned into pCDNA3 and consisted of
an N-terminal FLAG tag followed by residues 1–67 of murine CCM2, then the
Shc PTB domain (residues 45–236 from Shc) and finally the C-terminal CCM2
Karet domain (residues 228–453 of CCM2).
Oligonucleotide Microarray Analyses
Gene expression information for TrkA, TrkB, TrkC, CCM1, CCM2, CCM3, and
p75 were extracted from whole-genome single-color microarray profiles of
478 pretreatment primary neuroblastoma tumors, generated as single-color
experiments using a customized 43 44 K oligonucleotide microarray (Agilent).
After washing and scanning, resulting TIF images were processed using
Agilent’s Feature Extraction software, version 9.5.1.
Additional methods and descriptions of reagents are available in Supple-
mental Experimental Procedures online.
SUPPLEMENTAL DATA
Supplemental Data can be found with this article online at http://www.cell.
com/neuron/supplemental/S0896-6273(09)00632-1.
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